Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.52 |
| ▸ | NT5E | P21589 | 3/20 | 0.49 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.48 |
| ▸ | HINT1 | P49773 | 1/20 | 0.46 |
| ▸ | ADA | P00813 | 1/20 | 0.46 |
| ▸ | AHCY | P23526 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465589 | 0.91 | ADORA2A (0.62) | ADORA2ANT5EADAAHCYLMNA | |
| SCHEMBL465590 | 0.91 | ADORA2A (0.62) | ADORA2ANT5EADAAHCYLMNA | |
| SCHEMBL20991001 | 0.91 | ADORA2A (0.62) | ADORA2ANT5EADAAHCYLMNA | |
| SCHEMBL12849772 | 0.91 | ADORA2A (0.62) | ADORA2ANT5EADAAHCYLMNA | |
| SCHEMBL13929038 | 0.91 | ADORA2A (0.62) | ADORA2ANT5EADAAHCYLMNA | |
| SCHEMBL18061789 | 0.91 | ADORA2A (0.62) | ADORA2ANT5EADAAHCYLMNA | |
| SCHEMBL15038015 | 0.91 | ADORA2A (0.62) | ADORA2ANT5EADAAHCYLMNA | |
| SCHEMBL26326162 | 0.87 | ADORA3 (0.57) | ADORA2ANT5EADORA2BADORA3ADORA1 | |
| SCHEMBL12878148 | 0.86 | CA5A (0.56) | NT5EADORA1 | |
| SCHEMBL22837328 | 0.86 | CA5A (0.56) | NT5EADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140212382-A1 | PURINE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140212382-A1 | PURINE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | PNP, MTAP, NT5C3B | ADORA2A 83/4885NT5E 84/4885HSP90B1 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.